Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 6 of 25
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
17.03.2021
Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release
17.03.2021
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release
12.03.2021
Advent Life Sciences Becomes Latest Partner of One Nucleus
Press Release
02.03.2021
Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety
Press Release
18.02.2021
Advent Life Sciences Announces Close of Two New Funds Totalling $215 million
Press Release
16.02.2021
Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model
Press Release
25.01.2021
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem
Press Release
05.01.2021
Aura Biosciences Appoints David Johnson to Its Board of Directors
Press Release
22.10.2020
F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim
Press Release
13.10.2020
Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs
Press Release
©2022 Advent Life Sciences